Paul W. Shabram
Director Técnico/Científico/I+D en BIORA THERAPEUTICS, INC. .
Cargos activos de Paul W. Shabram
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| BIORA THERAPEUTICS, INC. | Director Técnico/Científico/I+D | 25/04/2022 | - |
Historial de carrera de Paul W. Shabram
Antiguos cargos conocidos de Paul W. Shabram.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| EMERGENT BIOSOLUTIONS INC. | Director Técnico/Científico/I+D | - | - |
| Ventana Biosciences, Inc. | Fundador | - | - |
Emergent Travel Health, Inc.
 Emergent Travel Health, Inc. Internet Software/ServicesTechnology Services Emergent Travel Health, Inc. develops vaccines against infectious diseases. The firm develops vaccines against typhoid, cholera, hepatitis, anthrax, and other infectious diseases. Its proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target viral or bacterial protein antigen. The company was founded by Kenneth Kelley and Daniel R. Henderson in 2007 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/07/2007 | - |
Formación de Paul W. Shabram.
| University of California, Santa Cruz | Undergraduate Degree |
| University of Phoenix | Masters Business Admin |
Estadísticas
Internacional
| Estados Unidos | 7 |
Operativa
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
Sectorial
| Consumer Services | 3 |
| Technology Services | 2 |
| Health Technology | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| EMERGENT BIOSOLUTIONS INC. | Health Technology |
| BIORA THERAPEUTICS, INC. | Health Services |
| Empresas privadas | 2 |
|---|---|
Emergent Travel Health, Inc.
Emergent Travel Health, Inc. Internet Software/ServicesTechnology Services Emergent Travel Health, Inc. develops vaccines against infectious diseases. The firm develops vaccines against typhoid, cholera, hepatitis, anthrax, and other infectious diseases. Its proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target viral or bacterial protein antigen. The company was founded by Kenneth Kelley and Daniel R. Henderson in 2007 and is headquartered in San Diego, CA. | Technology Services |
| Ventana Biosciences, Inc. |
- Bolsa de valores
- Insiders
- Paul W. Shabram
- Experiencia
